PSEN2 Presenilin 2 AD Causal Chain

Migration, Crosslink

📖

PSEN2 Presenilin 2 AD Causal Chain

active

wiki page Created: 2026-04-02T07:20:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-psen2-presenilin-2-ad-ca

📖 Wiki Page

mechanism2012 wordssynced 2026-04-02

PSEN2 Presenilin 2 AD Causal Chain

Overview

This synthesis page documents the complete causal chain from PSEN2 (Presenilin 2) genetic mutations to Alzheimer's disease phenotype, integrating genetic evidence, molecular mechanisms, cellular pathways, and therapeutic intervention points. PSEN2 is the second causative gene for familial Alzheimer's disease and provides unique insights into gamma-secretase biology and disease heterogeneity.

Genetic Evidence

PSEN2 Gene Overview

PSEN2 encodes Presenilin 2, the catalytic subunit of the gamma-secretase complex. While less frequently mutated than PSEN1, PSEN2 mutations cause both familial and potentially sporadic Alzheimer's disease.

| Property | Value |
|----------|-------|
| Chromosome | 1q42.13 |
| Protein | Presenilin 2 (448 amino acids) |
| Function | Aspartyl protease, gamma-secretase catalytic subunit |
| Inheritance | Autosomal dominant |
| Age of Onset | Typically 55-75 years (mean ~65) |

Key Pathogenic Mutations

Over 70 pathogenic mutations in PSEN2 have been identified. The most well-characterized include:

| Mutation | Location | Effect | Population |
|----------|----------|--------|-------------|
| N141I | TM2 | Severe Aβ42 increase, reduced activity | Volga German |
| M239V | TM6 | Increased Aβ42/Aβ40 ratio | Italian |
| T122P | TM4 | Impaired gamma-secretase | German |
| M239I | TM6 | Altered APP processing | - |
| A85V | TM2 | Partial loss of function | - |
| R62H | TM1 | Reduced proteolytic activity | - |

Genetic Evidence Score: 10/10

...

PSEN2 Presenilin 2 AD Causal Chain

Overview

This synthesis page documents the complete causal chain from PSEN2 (Presenilin 2) genetic mutations to Alzheimer's disease phenotype, integrating genetic evidence, molecular mechanisms, cellular pathways, and therapeutic intervention points. PSEN2 is the second causative gene for familial Alzheimer's disease and provides unique insights into gamma-secretase biology and disease heterogeneity.

Genetic Evidence

PSEN2 Gene Overview

PSEN2 encodes Presenilin 2, the catalytic subunit of the gamma-secretase complex. While less frequently mutated than PSEN1, PSEN2 mutations cause both familial and potentially sporadic Alzheimer's disease.

| Property | Value |
|----------|-------|
| Chromosome | 1q42.13 |
| Protein | Presenilin 2 (448 amino acids) |
| Function | Aspartyl protease, gamma-secretase catalytic subunit |
| Inheritance | Autosomal dominant |
| Age of Onset | Typically 55-75 years (mean ~65) |

Key Pathogenic Mutations

Over 70 pathogenic mutations in PSEN2 have been identified. The most well-characterized include:

| Mutation | Location | Effect | Population |
|----------|----------|--------|-------------|
| N141I | TM2 | Severe Aβ42 increase, reduced activity | Volga German |
| M239V | TM6 | Increased Aβ42/Aβ40 ratio | Italian |
| T122P | TM4 | Impaired gamma-secretase | German |
| M239I | TM6 | Altered APP processing | - |
| A85V | TM2 | Partial loss of function | - |
| R62H | TM1 | Reduced proteolytic activity | - |

Genetic Evidence Score: 10/10

Causality strength: Absolutely proven - PSEN2 mutations are fully penetrant causes of familial AD
Population frequency: Very rare (<0.001% of population)
Age of onset: Later than PSEN1 (~65 years average), consistent with "late-onset" FAD
Segregation: Perfect Mendelian inheritance in affected families
Unique feature: Some PSEN2 mutations show incomplete penetrance or variable expressivity

Molecular Mechanism

Gamma-Secretase Complex

PSEN2 functions as the catalytic core of the gamma-secretase complex, similar to PSEN1 but with distinct biochemical properties:

Mermaid diagram (expand to render)

Distinct Properties of PSEN2-Containing Complexes

PSEN2-containing γ-42 complexes differ from PSEN1 complexes in several ways:

Substrate affinity - PSEN2 shows different substrate preferences

Cleavage efficiency - Generally lower overall catalytic activity

Aβ profile - Tends to produce more Aβ43 in addition to Aβ42

Cellular distribution - More abundant in non-neuronal tissues

Amyloid Beta Production Pathway

PSEN2 mutations alter gamma-secretase cleavage through multiple mechanisms:

Mermaid diagram (expand to render)

Downstream Molecular Effects

Increased Aβ42/Aβ40 ratio - Most PSEN2 mutations increase the proportion of longer, aggregation-prone Aβ peptides

Aβ43 production - Some PSEN2 mutations produce elevated Aβ43, even more aggregation-prone than Aβ42

Partial loss-of-function - Paradoxically, many PSEN2 mutations reduce overall gamma-secretase activity while increasing Aβ42 proportion

ER calcium dysregulation - Mutant PSEN2 affects calcium homeostasis through ER-mitochondria contacts

Cellular Mechanisms

Mitochondrial Dysfunction

PSEN2 has unique roles in mitochondrial biology not shared with PSEN1:

Mermaid diagram (expand to render)

Autophagy and Lysosomal Dysfunction

PSEN2 mutations impair autophagy through multiple mechanisms:

Autophagosome accumulation - Reduced fusion with lysosomes
Lysosomal acidification defect - Impaired protease activity
TFEB nuclear translocation - Reduced autophagy gene expression
mTORC1 dysregulation - Altered nutrient sensing

Synaptic Dysfunction

PSEN2 mutations contribute to synaptic failure through:

Aβ-induced LTP impairment - Memory trace weakening
Calcium dysregulation - ER calcium leak through mutant presenilin
Synaptic protein trafficking - Altered delivery to synapses
Mitochondrial energy deficit - Insufficient ATP for synaptic function

Clinical Phenotype

Disease Progression

| Stage | Age | Clinical Features |
|-------|-----|-------------------|
| Preclinical | 55-60 | Normal cognition, biomarker changes (elevated Aβ42, tau) |
| Prodromal | 60-65 | MCI, episodic memory deficits |
| Mild AD | 65-70 | Working memory impairment, word-finding difficulty |
| Moderate AD | 70-75 | Disorientation, behavioral changes |
| Severe AD | 75+ | Global cognitive decline, motor symptoms |

Phenotypic Heterogeneity

PSEN2 mutations show distinct clinical features from PSEN1:

Later age of onset - Average ~65 years vs ~45 years for PSEN1
Atypical presentations - Some mutations cause spastic paraparesis
Variable penetrance - Some PSEN2 mutations show incomplete penetrance
Pathology diversity - Some cases show Lewy body co-pathology
Psychiatric symptoms - Higher frequency of depression and psychosis

Comparison with PSEN1

| Feature | PSEN1 | PSEN2 |
|---------|-------|-------|
| Age of onset | 30-60 years | 55-75 years |
| Disease duration | 8-12 years | 10-15 years |
| Myoclonus/seizures | Common | Less common |
| Spastic paraparesis | Rare | Some mutations |
| Atypical features | Less common | More common |

Therapeutic Intervention Points

Current Therapeutic Strategies

| Intervention | Mechanism | Development Stage | Target |
|--------------|-----------|-------------------|--------|
| Gamma-secretase modulators (GSMs) | Shift cleavage to less Aβ42 | Phase 2/3 | Aβ42 production |
| Anti-Aβ antibodies | Passive immunization | Phase 3 (lecanemab, donanemab) | Aβ plaques |
| Aβ oligomer inhibitors | Block toxic oligomers | Preclinical | Aβ42 oligomers |
| Notch-sparing inhibitors | Reduce Notch side effects | Preclinical | γ-secretase |
| PSEN2-selective modulators | Target PSEN2 complexes | Preclinical | PSEN2-γ42 |

PSEN2-Specific Considerations

Later age of onset - Longer therapeutic window for prevention

Incomplete penetrance - Potential for early intervention in carriers

Mitochondrial effects - Additional targets beyond Aβ

Lower Notch impact - PSEN2 complexes may have different Notch involvement

Gene-Specific Therapies

| Approach | Strategy | Challenges | Timeline |
|----------|----------|------------|----------|
| ASO therapy | Silence mutant PSEN2 | Allele-specific targeting | 5-10 years |
| CRISPR-Cas9 | Correct mutation | CNS delivery, efficiency | 10+ years |
| Protein folding drugs | Correct PSEN2 misfolding | Brain delivery | 5-10 years |
| Mitochondrial protectants | Restore mitochondrial function | Target mitochondria | 3-7 years |

Intervention Point Diagram

Mermaid diagram (expand to render)

Evidence Scores

| Category | Score | Rationale |
|----------|-------|-----------|
| Genetic Causality | 10/10 | Fully penetrant, autosomal dominant, >70 mutations identified |
| Mechanism Validation | 9/10 | Gamma-secretase complex well-characterized, distinct PSEN2 properties |
| Therapeutic Potential | 7/10 | Multiple approaches in development; later onset provides longer window |
| Clinical Translation | 7/10 | Biomarkers available but less clinical trial data than PSEN1 |
| Overall | 8.25/10 | Strong evidence for causal chain with unique features |

Cross-Disease Synthesis

Alzheimer's Disease Subtypes

Late-onset familial AD: PSEN2 accounts for ~5-10% of FAD cases
Sporadic AD modifier: PSEN2 variants may modify risk in LOAD
Atypical AD: Some PSEN2 mutations cause posterior cortical atrophy or spastic paraparesis

Cross-Disease Connections

| Disease | Connection | Evidence |
|---------|------------|----------|
| Parkinson's Disease | PSEN2 affects alpha-synuclein processing; mitochondrial complex I | Moderate |
| FTD | TDP-43 co-pathology in some cases | Weak-Moderate |
| ALS | Shared neuroinflammation pathways | Weak |
| Cerebral amyloid angiopathy | Aβ42 vascular deposition | Strong |

Shared Mechanisms with Other Neurodegeneration

Protein aggregation - Similar to α-synuclein (PD), TDP-43 (ALS)
Mitochondrial dysfunction - Universal feature across neurodegenerative diseases
ER stress - Shared with ALS (C9orf72, SOD1)
Autophagy impairment - Common across AD, PD, ALS

PSEN1 vs PSEN2 Comparison

| Feature | PSEN1 | PSEN2 |
|---------|-------|-------|
| Mutation count | 300+ | 70+ |
| Age of onset | 30-60 years | 55-75 years |
| Expression pattern | Ubiquitous | More restricted |
| Aβ profile | Aβ42 ↑↑ | Aβ42/Aβ43 ↑ |
| Mitochondrial role | Less prominent | Prominent |
| Notch processing | Primary | Secondary |

Knowledge Gaps and Research Priorities

Unresolved Questions

Mechanism heterogeneity - Why do different PSEN2 mutations cause different phenotypes?

Non-amyloid functions - What are the non-gamma-secretase roles of PSEN2 in neurons?

Incomplete penetrance - What genetic modifiers affect PSEN2 mutation expression?

PSEN2 vs PSEN1 - Why does PSEN2 cause later-onset disease?

Therapeutic targeting - How to selectively modulate PSEN2-containing complexes?

High-Priority Research Areas

| Priority | Research Area | Rationale |
|----------|---------------|-----------|
| 1 | PSEN2-selective GSMs | Target PSEN2-containing complexes specifically |
| 2 | Mitochondrial protectants | Exploit unique PSEN2 mitochondrial roles |
| 3 | Biomarker development | Earlier detection in PSEN2 carriers |
| 4 | Gene therapy | Direct correction of pathogenic mutations |

References

[Rogaev EI, Sherrington R, Rogaeva EA, et al, Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 1 gene (1995)](https://doi.org/10.1038/376775a0)

[Levy-Lahad E, Wasco W, Poorkaj P, et al, Candidate gene for the chromosome 1 familial Alzheimer's disease locus (1995)](https://doi.org/10.1126/science.7638622)

[Ryman NR, Ryman DC, Pankratz VS, et al, Presenilin 2 mutation (N141I) associated with late onset Alzheimer's disease in Volga German pedigrees (2001)](https://doi.org/10.1212/WNL.56.8.1115)

[Wolfe MS, Xia W, Ostaszewski BL, et al, Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity (1999)](https://doi.org/10.1038/19077)

[Steiner H, Duff K, Capell A, et al, A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling (1999)](https://doi.org/10.1074/jbc.274.40.28669)

[Zhou R, Yang G, Guo Y, et al, Recognition of the amyloid precursor protein by the gamma-secretase (2019)](https://doi.org/10.1126/science.aaw0930)

[Bai XC, Yan Z, Wu J, et al, An atomic structure of human gamma-secretase (2015)](https://doi.org/10.1038/nature14892)

[Lee JH, Yu WH, Kumar A, et al, Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PSEN1 mutations (2010)](https://doi.org/10.1016/j.cell.2010.05.008)

[Liu J, Li L, Targeting autophagy for the treatment of Alzheimer's disease: challenges and opportunities (2022)](https://doi.org/10.3389/fncel.2022.1060210)

[van Dyck CH, Swanson CJ, Aisen P, et al, Lecanemab in early Alzheimer's disease (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Hansson CA, Frykman S, Farmery MR, et al, Nicastrin, presenilin, APH-1, and PEN-2 are present in mitochondria (2004)](https://doi.org/10.1074/jbc.M409686200)

[Zampese E, Fasolato C, Penzo D, et al, Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca2+ crosstalk (2011)](https://doi.org/10.1073/pnas.1108245108)

[Shen J, Kelleher RJ, The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism (2007)](https://doi.org/10.1073/pnas.061005598)

[Wines-Samuelson M, Shen J, Presenilins in the brain: what's new? (2005)](https://doi.org/10.1016/j.neuron.2005.04.002)

[Gao J, Nalls M, Shi M, et al, An exploratory analysis on gene variants in Parkinson disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19918080/)

[Chivet M, Hemming F, Fraboulet S, et al, Role of presenilin in the pathogenesis of alpha-synucleinopathies (2009)](https://pubmed.ncbi.nlm.nih.gov/19721438/)

[Devi L, Prabhu BM, Galati DF, et al, Accumulation of amyloid precursor protein in the mitochondrial import channels of brain's cholinergic neurons with implications for Alzheimer's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/17035524/)

[Schapira AH, Mitochondrial dysfunction in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29394333/)

[Pettersson M, Kauffman GW, Am Ende CW, et al, Novel gamma-secretase modulators for the treatment of Alzheimer's disease (2023)](https://doi.org/10.1007/978-3-031-21436-4_19)

[Doody RS, Raman R, Farlow M, et al, A phase 3 trial of semagestat for Alzheimer's disease (2013)](https://doi.org/10.1056/NEJMoa1207517)

[Bateman RJ, Xiong C, Benzinger TL, et al, Clinical and biomarker changes in dominantly inherited Alzheimer's disease (2012)](https://doi.org/10.1056/NEJMoa1207517)

[Hung CL, Livesey FJ, Current approaches to prevent and treat Alzheimer's disease (2023)](https://doi.org/10.1038/s41380-023-01117-3)

📖 View canonical wiki page →

Related Entities

mechanisms-psen2-presenilin-2-ad-causal-chain

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-psen2-presenilin-2-ad-causal-chain
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b3697eb72653
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-psen2-presenilin-2-ad-causal-chain'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

36

Outgoing

41

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PSEN2 Presenilin 2 AD Causal Chain

PSEN2 Presenilin 2 AD Causal Chain

Overview

Genetic Evidence

PSEN2 Gene Overview

Key Pathogenic Mutations

Genetic Evidence Score: 10/10

PSEN2 Presenilin 2 AD Causal Chain

Overview

Genetic Evidence

PSEN2 Gene Overview

Key Pathogenic Mutations

Genetic Evidence Score: 10/10

Molecular Mechanism

Gamma-Secretase Complex

Distinct Properties of PSEN2-Containing Complexes

Amyloid Beta Production Pathway

Downstream Molecular Effects

Cellular Mechanisms

Mitochondrial Dysfunction

Autophagy and Lysosomal Dysfunction

Synaptic Dysfunction

Clinical Phenotype

Disease Progression

Phenotypic Heterogeneity

Comparison with PSEN1

Therapeutic Intervention Points

Current Therapeutic Strategies

PSEN2-Specific Considerations

Gene-Specific Therapies

Intervention Point Diagram

Evidence Scores

Cross-Disease Synthesis

Alzheimer's Disease Subtypes

Cross-Disease Connections

Shared Mechanisms with Other Neurodegeneration

PSEN1 vs PSEN2 Comparison

Knowledge Gaps and Research Priorities

Unresolved Questions

High-Priority Research Areas

References

💬 Discussion